{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["apalutamide","abiraterone","leuprolide"]],"indication":"newly diagnosed oligometastatic prostate cancer","name":"NCT03298087","nct_id":"NCT03298087","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03298087. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.","label":"Experimental Arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-03-31","type":"ACTUAL"},"conditions":["Newly Diagnosed Oligometastatic Prostate Cancer"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"radical prostatectomy","otherNames":[],"type":"PROCEDURE"},{"name":"stereotactic body radiotherapy","otherNames":["SBRT"],"type":"RADIATION"},{"name":"Leuprolide","otherNames":["ADT"],"type":"DRUG"},{"name":"apalutamide","otherNames":["ARN-509"],"type":"DRUG"},{"name":"abiraterone","otherNames":["zytiga"],"type":"DRUG"}],"last_update":"2025-08-01","lead_sponsor":"VA Office of Research and Development","official_title":"Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-03-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation)","timeFrame":"6 months after recovery of testosterone"}],"references":[{"citation":"Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.","pmid":"30935383","type":"DERIVED"}],"start_date":{"date":"2018-07-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03298087"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03298087"}